Sites: Nominate Innovative Enrollment Plans for Award
An independent judging panel will select three finalists from the submissions.
The Society for Clinical Research Sites (SCRS), a global trade organization for clinical research sites, announced that it is accepting submissions for its annual Site Patient Recruitment Innovation Award (SPRIA), which recognizes sites that employ innovative strategies to achieve enrollment success. An independent judging panel will select three finalists from the submissions. The finalists will be invited to attend the Site Solutions Summit with a complimentary registration. At the summit, the finalists will present their plans to an audience of executives from sites, sponsors, and CROs. The judging panel then will determine the winner. Nominations forms can be downloaded on the Global Site Solutions Summit website. Completed form should be sent to SPRIA@myscrs.org by July 31, 2015.
The Global Site Solutions Summit takes place October 8-11, at Amelia Island, FL.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
